Previous work indicates that EMT-6 tumours, characterised by high TGF-β levels, respond poorly to PD-1/PD-L1 inhibitors due to T cell exclusion mediated by CAF-driven stromal barriers [26]. The gene discussed is TGFB1; the disease is neoplasm.